PEP-Therapy is a clinical-stage biotechnology company developing first-in-class peptides as targeted therapies in oncology based on the Company’s innovative Cell Penetrating and Interfering Peptides (CP&IP) technology. These innovative molecules penetrate cells and specifically block relevant intracellular protein-protein interactions, leading to the inhibition of key pathological mechanisms without altering physiological mechanisms.
PEP-010, first CP&IP-based drug candidate, is a pro-apoptotic agent which has demonstrated anti-tumor efficacy in a number of pre-clinical models and a good safety profile.
PEP-010 is currently evaluated in a Phase Ia/b clinical trial in patients with recurrent and/or metastatic solid tumors.
PEP-Therapy was founded in 2014 and builds on research results from Institut Curie and Sorbonne University. The company is backed by international investors.
Location: France, Ile-de-France
Employees: 1-10
Total raised: $4.48M
Founded date: 2014
Investors 1
| Date | Name | Website |
| 22.03.2022 | Business A... | business-a... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 20.07.2021 | Series A | $3.06M | - |
| 27.04.2015 | - | $1.41M | - |
Mentions in press and media 4
| Date | Title | Description | Source |
| 25.04.2024 | PEP-Therapy et l’Institut Curie annoncent le traitement des ... | Communiqué de presse PEP-Therapy et l’Institut Curie annoncent le traitement des premiers patients d... | einpresswi... |
| 25.04.2024 | PEP-Therapy and Institut Curie Announce First Patients Dosed... | Press release PEP-Therapy and Institut Curie Announce First Patients Dosed in Phase Ib Clinical Tria... | einpresswi... |
| 20.07.2021 | PEP-Therapy Raises €2.6M in Series A Extension Financing | PEP-Therapy, a Paris, France-based biotechnology company, raised an additional €2.6m ($3m) in an ext... | finsmes.co... |
| 27.04.2015 | PEP-Therapy Raises €1.3M in Funding | PEP-Therapy, a Paris, France-based biotechnology company developing targeted therapies for cancer tr... | finsmes.co... |